Literature DB >> 17629808

Lung cancer screening: current situation and perspective.

Idris Guessous1, Jacques Cornuz, Fred Paccaud.   

Abstract

Worldwide, lung cancer is the most common cancer in terms of both incidence and mortality with 1,04 million new cases per year and 921,000 deaths, with the highest rates currently observed in Europe and North America. Once diagnosed, the 5-year survival rate for lung cancer in Europe fluctuates between 8% and 12%. Smoking is found in 90% of lung cancer cases. A successful, straightforward preventive strategy to reduce the incidence of the disease is a sustained prevention of tobacco consumption. However, because of the persistent risk among former smokers, early treatment following early diagnosis is still considered as potential development. There is currently no recommended screening strategy for lung cancer, reflecting the negative results of trials showing no mortality reduction following screening programs using chest X-ray and sputum examination. Low dose computed tomography has been recently assessed as a screening tool in observational studies suggesting better impact than the one obtained with chest X-ray. Five RCTs are currently under way to evaluate low dose computed tomography as a screening tool for lung cancer, with a total of 133,000 subjects. First results are expected for 2007. Until the completion of these studies, wild screening intervention should be avoided.

Entities:  

Mesh:

Year:  2007        PMID: 17629808     DOI: 2007/21/smw-11582

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  9 in total

Review 1.  Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review).

Authors:  Mudit Vaid; Joanna Floros
Journal:  Oncol Rep       Date:  2009-01       Impact factor: 3.906

2.  Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

Authors:  Benoît Busser; Lucie Sancey; Véronique Josserand; Carole Niang; Marie C Favrot; Jean-Luc Coll; Amandine Hurbin
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454

3.  Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.

Authors:  Seyed Javad Moghaddam; Huaiguang Li; Sung-Nam Cho; Megan K Dishop; Ignacio I Wistuba; Lin Ji; Jonathan M Kurie; Burton F Dickey; Francesco J Demayo
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-16       Impact factor: 6.914

4.  Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice.

Authors:  S J Moghaddam; P Barta; S G Mirabolfathinejad; Z Ammar-Aouchiche; N Torres Garza; T T Vo; Robert A Newman; Bharat B Aggarwal; Christopher M Evans; Michael J Tuvim; Reuben Lotan; Burton F Dickey
Journal:  Carcinogenesis       Date:  2009-09-30       Impact factor: 4.944

5.  Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells.

Authors:  Qi Zhang; Yan Ma; Yue-Fang Cheng; Wen-Jie Li; Zhenzhong Zhang; Shao-Yu Chen
Journal:  Cancer Lett       Date:  2011-09-17       Impact factor: 8.679

Review 6.  [Progress of treatments in non-small cell lung cancer with brain metastases].

Authors:  Chunhua Ma; Rong Jiang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-05

7.  Extraction, Structural Characterization, and Anti-Hepatocellular Carcinoma Activity of Polysaccharides From Panax ginseng Meyer.

Authors:  Hui Jia; Bin Zhao; Fangfang Zhang; Ramesh Kumar Santhanam; Xinying Wang; Jincai Lu
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 8.  Why and how would we implement a lung cancer screening program?

Authors:  Idris Guessous; Jacques Cornuz
Journal:  Public Health Rev       Date:  2015-11-05

9.  Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.

Authors:  Yongyong Wang; Xiaowu Fan; Xiaowei Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.